3'-Azido-3'-deoxythymidine (AZT) is a drug of choice for the treatment of AIDS. On the basis of pharmacokinetic data, the nonhuman primate Macaca nemestrina has been shown to be a suitable animal model for use in the study of the disposition of AZT. However, since AZT is activated to its metabolite, the AZT triphosphate (AZTTP), intracellularly, we investigated the intracellular activation of AZT in peripheral blood mononuclear cells (PBMCs) of healthy and simian immunodeficiency virus-infected macaques and compared it with that in PBMCs obtained from human volunteers. At 5 ,uM extracellular AZT, both human and macaque PBMCs rapidly convert AZT to AZT monophosphate (AZTMP) (84% of total phosphorylated products) in 4 h.
The human immunodeficiency virus (HIV), a lymphotropic retrovirus, is known to be the etiologic agent of AIDS and AIDS-related complex. In order to expedite research on and the development of new anti-HIV drugs, there is an urgent need to develop and validate a representative animal model that can be used to test the efficacy and safety of new anti-HIV drugs. The simian immunodeficiency virus (SIV)-infected nonhuman primate is believed to be one such representative animal model (for reviews, see references 20 and 33). SIV is a retrovirus-like group of viruses that produce an AIDS-like syndrome similar to that produced by HIV in a variety of nonhuman primates. SIV has genetic, antigenic, and biological similarities to HIV types 1 and 2, the viruses that cause AIDS (19, 21) .
The dideoxynucleoside analog 3'-azido-3'-dideoxythymidine (AZT) is the first clinically approved drug for the treatment of AIDS (for a review, see reference 34). Intracellularly, this prodrug is metabolized through a series of cellular kinases to its active moiety, the AZT triphosphate (AZTTP). AZT[P inhibits the HIV enzyme reverse transcriptase by prematurely chain terminating the synthesis of proviral DNA (5, 13, 34) . AZTTP is also capable of inhibiting DNA polymerases alpha and beta (6, 10, 13, 27) and gamma (13) . Therefore, the intracellular concentration of AZTT7P is an important determinant of the efficacy and toxicity of AZT. Interestingly, the extracellular concentration of AZT is not linearly correlated with the intracellular concentration of AZTTP (10, 12, 28) .
Data from our laboratory and other laboratories have in-
Research Center of the University of Washington. Five of these macaques were infected with SIV and four were SIV nefative. The SIV-infected macaques were exposed to 104 to 10 50% tissue culture infective doses of SIV intrarectally. Two to 4 months prior to conducting the experiments, the infected macaques were determined to be SIV positive by viral antigen test (p27 core antigen of SIV), antibody detection, and PCR of PBMCs. Isolation of PBMCs. Fresh venous blood (maximum of 20 and 200 ml per macaque and human subject, respectively) was collected in heparinized Vacutainer tubes. Following dilution with an equal volume of cold phosphate-buffered saline (PBS), 20-ml aliquots of the diluted blood were loaded onto 20 ml of LSM in a 50-ml conical centrifuge tube, and the tubes were centrifuged at 400 x g for 20 min to isolate the PBMCs. For isolation of macaque PBMCs, 95% LSM (diluted with PBS) was used. The isolated PBMCs were washed two times in RPMI 1640 medium and were finally resuspended in the culture medium for cell counting and incubation. Differential cytology examination was performed to measure the purity of the isolated cells. PBMCs constituted 94% ± 3% and 93% + 5% of the isolated cells from human and macaque blood, respectively.
Incubation of PBMCs with AZT, extraction, and analysis of the phosphorylated metabolites. The isolated PBMCs were incubated in RPMI 1640 medium (Gibco) containing 10% FCS supplemented with 100 U of penicillin per ml, 100 ,ug of streptomycin per ml, and 0.25 ,ug of amphotericin B (Fungizone; Gibco) per ml. Various (0.45, 0.9, 1.8, 3.6, 7.2, and 14.4 ,uM) or fixed (5 jiM) [3H]AZT concentrations were added to the PBMC medium, and the cells were maintained at 37°C in 5% CO2 for constant (4 h) or various (1, 2, 4, 8, 16 , and 24 h) times prior to removal for extraction. The PBMCs were scraped from the tissue culture plates at the indicated time points and were extracted and analyzed for AZT metabolites by gradient HPLC and scintillation counting by a method previously described by our laboratory (24) . the time course of the study, the levels of AZTDP and AZTTP constituted less than 12 and 15%, respectively, of the total phosphorylated metabolites. After achieving the peak, the intracellular level of AZTMP declined approximately 50% over the next 20 h of incubation, while AZTDP and AZTTP levels decreased only slightly during the 8-to 24-h incubation period.
RESULTS

Kinetics
The time course of AZT phosphorylation in human PBMCs was similar to that of macaque PBMCs (Fig. 1B) AZTTP profiles in human PBMCs were similar to those in macaque PBMCs over the same time period.
Concentration-dependent intracellular phosphorylation of AZT in PBMCs. To determine the concentration effect of AZT on its intracellular metabolism over a clinically relevant concentration range, PBMCs were incubated with 0.45 to 14.4 jiM (6.3 to 203 jiCi) AZT for 4 h. The distributions of phosphorylated AZT products were assayed in both macaque and human cells. In macaque PBMCs, a 32-fold increase in the AZT concentration (from 0.45 to 14.4 jiM) resulted in a 12-fold increase in the intracellular AZTMP level (from 0.2 to 2.4 pmol/107 cells). The rise in either AZTDP or AZTTP level was less than threefold ( Fig. 2A) . Similarly, in human PBMCs, a 7.7-fold increase in intracellular AZTMP levels was detected over the same AZT concentration range. The increases in AZTDP and AZTTP levels in human PBMCs were also quite similar (two-to fourfold increase) to those in macaque PBMCs (Fig. 2B) <7 .5% for all metabolites). In contrast, the intersubject variability (n = 5) in the levels of intracellular AZT metabolites was much greater (Fig. 4B) , being prominent for AZTMP (CV, <60%) and least prominent for AZT (CV, <10%).
AZT phosphorylation in healthy and SIV-infected macaque PBMCs. PBMCs isolated from healthy (n = 4) and SIVinfected (n = 5) macaques were incubated with 0.9 ,uM [3H] AZT for a 4-h period, and intracellular metabolite levels were determined. The average levels of intracellular AZT, AZTMP, AZTDP, and AZTTP in healthy macaque PBMCs were 0.30 ± 0.09, 0.4 + 0.06, 0.05 ± 0.01, and 0.04 ± 0.01 pmol/107 cells, respectively (Fig. 5) . Under the same experimental conditions, the average levels (in picomoles per 10' cells) of intracellular AZT (1.58 ± 0.24), AZTMP (2.17 ± 1.12), AZTDP (0.13 ± 0.02), and AZT7lP (0.13 ± 0.02) in SIV-infected PBMCs were 5.3-, 5.5-, 2.5-, and 2.9-fold greater than those in uninfected PBMCs, a difference which was highly significant (Fig. 5) . DISCUSSION The kinetics of intracellular AZT phosphorylation in human PBMCs showed that AZT is rapidly converted to AZTMP (Fig. 1B) . Similar observations for human PBMCs (1, 29) and human placental trophoblast and Hofbauer cells (24) have been reported previously. Beyond the 4-h period, an additional increase in intracellular metabolite levels was observed. The kinetics of intracellular AZT phosphorylation to AZTMP in macaque PBMCs were also found to be rapid (Fig. 1A) . In contrast to human PBMCs, a decrease in AZTMP levels was observed after 4 h in macaque PBMCs. A similar phenomenon was also observed in human placental trophoblast cells (24) ; human lymphocytic lines HL60, H9, and K-562 (8), ATH8, Molt/4F, and MT4 (3, 4), CEM (2), and CCRE-CEM (9); and activated human PBMCs (1). The mechanism for this decline in AZTMP levels is not clear.
A large increase (7.7-fold) in intracellular AZTMP levels was detected in both human and macaque PBMCs over the extracellular AZT concentration range of 0.45 to 14.4 ,uM (Fig.  2) . In contrast, the time-dependent accumulation of intracellular AZTDP and AZTTP levels was smaller for these cells. These observations are in agreement with those reported previously over a similar AZT concentration range in both activated and resting PBMCs (29) . These data support the notion that the rate-limiting step of AZT phosphorylation is the conversion of AZTMP to AZTDP by thymidylate kinase, as evidenced by the significantly lower AZTDP/AZTlP ratio when compared with the AZTMP/AZTTP ratio (Fig. 3) . Both human and macaque PBMC studies showed that 0 to 8 puM extracellular AZT produced an increase in intracellular AZT levels and in the levels of its phosphorylated metabolites. However, higher extracellular AZT concentrations (8 to 16 ,uM) failed to produce further increases in the levels of intracellular phosphorylated products (Fig. 2) . Hence, an increase in the extracellular AZT concentration produces diminishing returns in terms of the amount of the active moiety (AZT'TP) that is formed. These data therefore probably explain the clinical findings that a 100-mg dose is as effective as a 250-mg dose of AZT (7) .
Although the intraindividual variation (CV, <7.5% for all metabolites) in AZT phosphorylation in healthy human PBMCs is low (Fig. 4A) , indicating the excellent reproducibility of the assay, the interindividual variability in phosphorylation of AZT is significant (CVs, 60% for AZTMP, 41% for AZTDP, and 33% for AZTTP; Fig. 4B) . A similar interindividual variation in AZTMP levels was observed in the PBMCs of SIV-infected macaques (CV, 54%) but not in the PBMCs of healthy macaques (Fig. 5) . Although this variability has previously been reported for human PBMCs by Kuster et al. (15) and Tornevik et al. (29) , the underlying basis for the variation is not clear.
Comparison of AZT phosphorylation between healthy and SIV-infected macaque PBMCs showed that the levels of AZT metabolites were significantly (2.5-to 5-fold) higher in SIVinfected macaques (Fig. 5) therefore the intracellular concentration of the AZT metabolites. On the basis of that computation, the mean AZTMP concentrations were found to be similar (1.2 p,M) in both SIV-infected and uninfected cells. However, the mean concentrations of AZTDP and AZTTP were found to be twofold lower in SIV-infected PBMCs (Table 1) , suggesting the possible use of these intracellular AZT metabolites in the presence of productive SIV infection. We recognize that because of the efflux of AZT during the washing procedure, the calculated volumes may be underestimates. However, since the inter-and intraindividual variabilities in the AZT levels were small, the relative magnitudes of the difference in these levels in SIVinfected and uninfected cells should be an accurate reflection of the differences in AZT levels prior to washing.
The mechanism for the increase in AZT phosphorylation in HIV-or SIV-infected PBMCs is not known. Arner et al. (1) recently reported a fivefold increase in AZT phosphorylation in HIV-infected PBMCs. They hypothesized that a mitogenlike stimulatory factor(s) in the HIV-bearing supernatant may be responsible for an induction in thymidine kinase activity. However, in their study the increase in thymidine kinase activity was found to be only twofold. Alternatively, a change in cellular volume may explain the increase in AZTMP levels (on a per-cell basis) because of lymphocyte activation in HIV-and SIV-infected macaque PBMCs. Because of the well-documented increase in the cellular volume of lymphocyte activation by phytohemagglutinin or HIV infection (1, 14, 23) , the cellular concentration (micromolar) rather than amount (picomoles per 107 cells) may better reflect cellular metabolite profiles. When the cellular AZTMP contents expressed as amounts per cell are converted to intracellular concentration (1.2 ,uM), there was no difference in the AZTMP concentration in infected versus uninfected macaque PBMCs. Interestingly, the intracellular concentrations of AZTDP and AZTTP were lower in the SIV-infected PBMCs. This may be a reflection of the use of AZTTP by the productively infected cells.
In conclusion, healthy and SIV-infected macaque PBMCs showed an AZT phosphorylation profile comparable to that of healthy and HIV-infected human PBMCs. Thus, these data provide further evidence that the macaque, M. nemestrina, is a suitable animal model for use in the study of factors affecting in vivo intracellular AZT metabolism during infection with an immunodeficiency virus.
